Pulmo BioTech Inc. is a venture capital company focused solely on medical research, development and marketing. They are dedicated to bringing revolutionary new medical techniques and technologies to those in need of medical solutions. Recently, Pulmo BioTech announced the possibility of a new application for its PulmoBind molecular imaging technology.
Pulmo believes that there are several useful applications for its product line in conjunction with traditional MRI scanners. The company announced that it has had preliminary success with also tagging its molecular imaging candidates with a magnetic resonance contrast agent. If this work is successful, it will allow the medical community to use MRI scanners for lung vascular studies and potentially increase the addressable market for PulmoBind.
The PulmoBind molecular imaging technology by itself is designed to allow the imaging of the vascular system of the lungs by a diagnostic clinician and thus enable the diagnosis of pulmonary embolism, pulmonary hypertension and lung inflammatory conditions. These products have the potential to completely replace the conventional technology being used for a nuclear medicine-based diagnosis of several medical problems. Based on the preliminary trials and the rapid pace at which medicine has been advancing in the last decade, Pulmo BioTech Incorporated should remain on the radar of smart investors.
Let us hear your thoughts: Pulmo BioTech, Inc. Message Board